Skip to content
drillr.ai
Sign up

NXGL

NEXGEL, Inc.

NASDAQ · Healthcare · Medical - Instruments & Supplies · US

$0.32
−6.75%
Ask drillr

  • Aug 21, 2026, 00:00 UTC

    NexGel, Inc. appointed Kevin Harris as Chair of the Special Committee for Strategic Review and Value Creation, effective August 20, 2026.

  • Aug 20, 2026, 20:05 UTC

    NEXGEL, Inc. formed a Special Committee for Strategic Review and Value Creation.

    Source:

  • Aug 20, 2026, 20:05 UTC

    NEXGEL, Inc. appointed Brian Kieser as Interim Chief Executive Officer.

    Source:

  • Aug 17, 2026, 00:00 UTC

    NEXGEL, Inc. reported Q2 2026 revenue of $3.69 million and a net loss of $2.87 million.

  • May 28, 2026, 00:00 UTC

    Celularity Inc entered into a settlement agreement with Helena Global Investment Opportunities 1 Ltd to resolve default claims, obligating Celularity to pay $500,000 immediately plus five monthly $100,000 installments and assign a $2.5 million principal promissory note from NEXGEL Inc to Helena, with obligations secured by existing collateral.